Instinct Bio Technical Co. Holdings Inc.

Snapshot

BIOT is a tiny $10.9M company that just completed a SPAC merger on July 23, 2026, bringing in only about $131,905 in cash against a total equity deficit of $1.5 million.

What's Happening Right Now

• Thu 1st Oct '26 · Business development: On Oct 1, 2026, BIOT was named a non-exclusive representative to help introduce CelSiege Biosciences' early-stage lung cancer immunotherapy candidate to partners in Japan and China, with no financial terms disclosed.
• Tue 15th Sep '26 · Delisting risk: On Sept 15, 2026, BIOT disclosed three Nasdaq deficiency notices after its market value and share price fell below required minimums, giving it until March 2027 to regain compliance or possibly face a reverse split or delisting.
• Wed 9th Sep '26 · Partnership: On Aug 10, 2026, BIOT signed a cooperation agreement with Indonesian cosmetics firm PT Parva Candela to jointly develop and distribute cosmetics products under its GENRÊVER and HAKUA brands.
• Fri 14th Aug '26 · Merger closed: BIOT completed its business combination with Relativity Acquisition Corp on July 23, 2026, valuing the combined entity at $225 million, with pro forma cash of only about $131,905 and a total equity deficit of $1.5 million.
• Tue 11th Aug '26 · Equity facility: BIOT entered a non-binding term sheet for a $150 million equity purchase facility letting it sell shares over three years at a discount to market price to fund working capital and acquisitions.